ArticleBioengineering (Basel, Switzerland)2025
Marker-Less Lung Tumor Tracking from Real-Time Color X-Ray Fluoroscopic Images Using Cross-Patient Deep Learning Model.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patient-Specific Deep Reinforcement Learning for Proton Beam Delivery Under Inter-Phase Variations.International journal of particle therapy · 2026Article
- Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities.Tomography (Ann Arbor, Mich.) · 2026Review
- Evaluation of the reliability of markerless tumor tracking with single-energy and dual-energy imaging using machine learning.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fiducial marker implantation for tumor localization in radiotherapy is effective but invasive and carries complication risks. To address this, we propose a marker-less tumor tracking framework to explore the feasibility of a cross-patient deep learning model, aiming to eliminate the need for per-patient retraining. A novel degradation model generates realistic simulated data from digitally reconstructed radiographs (DRRs) to train a Restormer network, which transforms clinical fluoroscopic images into clean, DRR-like images. Subsequently, a DUCK-Net model, trained on DRRs, performs tumor segmentation. We conducted a feasibility study using a clinical dataset from 7 lung cancer patients, comprising 100 distinct treatment fields. The framework achieved an average processing time of 179.8 ms per image and demonstrated high accuracy: the median 3D Euclidean tumor center tracking error was 1.53 mm, with directional errors of 0.98±0.70 mm (LR), 1.09±0.74 mm (SI), and 1.34±0.94 mm (AP). These promising results validate our approach as a proof-of-concept for a cross-patient marker-less tumor tracking solution, though further large-scale validation is required to confirm broad clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.